is tirzepatide approved for weight loss New drug could break sales records Tirzepatide: A Breakthrough Approach to

Another issue is the practice of prescribing medications based on patient surveys, without direct contact with a medical professional

But my options were only expanding

For UHC Medicare Advantage members with established cardiovascular disease who are overweight or obese, the cardiovascular risk reduction indication is coverable under Part D with prior authorization OptumRx's 12-month authorization applies, and the February 2026 update removed the BMI requirement from CV reauthorization criteria

doi:10.1016/j.heares.2021.108209

Initial reviews at 24 weeks allow early identification of side effects and provide opportunities for patient support and education

MT-1 primarily targets MC1R (melanocortin-1 receptor) with high selectivity